Emergent Biosolutions
EBS
141 hedge funds and large institutions have $208M invested in Emergent Biosolutions in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 35 increasing their positions, 36 reducing their positions, and 29 closing their positions.
126% more capital invested
Capital invested by funds: $91.6M → $208M (+$116M)
69% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 29
16% more funds holding
Funds holding: 122 → 141 (+19)
3% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 36
11.15% less ownership
Funds ownership: 69.21% → 58.06% (-11%)
47% less call options, than puts
Call options by funds: $3.09M | Put options by funds: $5.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$2.68M |
| 2 |
CCM
Carronade Capital Management
Darien,
Connecticut
|
+$2.37M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.77M |
| 4 |
JP Morgan Chase
New York
|
+$1.62M |
| 5 |
Jane Street
New York
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$13.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.83M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$4.24M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.7M |
| 5 |
Renaissance Technologies
New York
|
-$3.09M |
EBS Hedge Fund Activity: Q2 2024 in Review
141 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2024, worth a combined $208M — up 126% from $91.6M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new EBS positions and 29 closed out — a net gain of 20 holders — while 35 added to existing stakes and 36 trimmed.
The largest buyer was American Century Companies, adding an estimated $2.68M. The largest seller was BlackRock, cutting an estimated $13.9M.
- 141 institutional investors held Emergent Biosolutions (EBS) as of Q2 2024, up from 122 in Q1 2024.
- Funds reported $208M of Emergent Biosolutions stock for Q2 2024, up 126% quarter-over-quarter.
- 49 funds opened new Emergent Biosolutions positions in Q2 2024 and 29 closed out, a net change of +20 holders.
- The largest Emergent Biosolutions buyer in Q2 2024 was American Century Companies, an estimated $2.68M added.
- The largest Emergent Biosolutions seller in Q2 2024 was BlackRock, an estimated $13.9M sold.
Based on aggregated 13F filings for Q2 2024.